Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LGND – Ligand Pharmaceuticals Incorporated

Float Short %

4.8

Margin Of Safety %

-35

Put/Call OI Ratio

0.51

EPS Next Q Diff

1.78

EPS Last/This Y

7.1

EPS This/Next Y

0.57

Price

158.99

Target Price

167.71

Analyst Recom

1

Performance Q

57.05

Relative Volume

1.14

Beta

0.97

Ticker: LGND




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25LGND135.780.490.00660
2025-07-28LGND135.020.490.94659
2025-07-29LGND131.460.52999.99680
2025-07-30LGND135.470.520.00680
2025-07-31LGND132.580.510.20695
2025-08-01LGND132.780.51999.99696
2025-08-04LGND135.250.510.00698
2025-08-05LGND135.30.510.00703
2025-08-06LGND143.250.513.50706
2025-08-07LGND146.720.520.06732
2025-08-08LGND150.110.500.24766
2025-08-11LGND146.990.490.15807
2025-08-12LGND152.670.500.30801
2025-08-13LGND1570.490.21810
2025-08-14LGND153.570.480.00825
2025-08-15LGND150.910.470.04839
2025-08-18LGND153.350.375.92599
2025-08-19LGND153.320.372.57599
2025-08-20LGND155.280.520.25705
2025-08-21LGND157.260.520.00708
2025-08-22LGND1590.512.50713
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25LGND135.831.5201.26.12
2025-07-28LGND134.771.5199.86.12
2025-07-29LGND131.581.5199.06.12
2025-07-30LGND135.231.5201.46.12
2025-07-31LGND131.581.5198.96.12
2025-08-01LGND132.721.5200.56.12
2025-08-04LGND135.391.5201.16.12
2025-08-05LGND135.151.5200.16.12
2025-08-06LGND143.121.5202.96.12
2025-08-07LGND146.321.5201.46.12
2025-08-08LGND150.061.5201.16.12
2025-08-11LGND146.991.5198.16.12
2025-08-12LGND152.60-0.1124.26.66
2025-08-13LGND156.010.6123.56.66
2025-08-14LGND153.770.6121.96.76
2025-08-15LGND151.190.6121.86.76
2025-08-18LGND153.520.6123.36.76
2025-08-19LGND154.070.6122.86.76
2025-08-20LGND155.380.6122.96.76
2025-08-21LGND157.293.3123.26.88
2025-08-22LGND158.993.3123.06.88
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25LGND0.622.916.56
2025-07-28LGND0.622.836.56
2025-07-29LGND0.622.836.56
2025-07-30LGND0.622.836.56
2025-07-31LGND0.622.836.56
2025-08-01LGND0.622.836.56
2025-08-04LGND0.622.666.56
2025-08-05LGND0.522.666.56
2025-08-06LGND0.522.666.56
2025-08-07LGND0.522.666.56
2025-08-08LGND0.522.666.56
2025-08-11LGND0.522.516.56
2025-08-12LGND0.532.514.87
2025-08-13LGND0.522.514.80
2025-08-14LGND0.522.514.80
2025-08-15LGND0.522.514.80
2025-08-18LGND0.522.074.80
2025-08-19LGND0.522.074.80
2025-08-20LGND0.522.074.80
2025-08-21LGND0.522.074.80
2025-08-22LGND0.522.074.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.24

Avg. EPS Est. Current Quarter

1.9

Avg. EPS Est. Next Quarter

2.02

Insider Transactions

0.52

Institutional Transactions

2.07

Beta

0.97

Average Sales Estimate Current Quarter

58

Average Sales Estimate Next Quarter

62

Fair Value

104.03

Quality Score

55

Growth Score

41

Sentiment Score

89

Actual DrawDown %

-0.7

Max Drawdown 5-Year %

-65.5

Target Price

167.71

P/E

Forward P/E

21.19

PEG

P/S

16.62

P/B

3.73

P/Free Cash Flow

58.58

EPS

-4

Average EPS Est. Cur. Y​

6.88

EPS Next Y. (Est.)

7.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-40.44

Relative Volume

1.14

Return on Equity vs Sector %

-33.8

Return on Equity vs Industry %

-20.9

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.74

EBIT Estimation

123
Ligand Pharmaceuticals Incorpor
Sector: Healthcare
Industry: Biotechnology
Employees: 68
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
stock quote shares LGND – Ligand Pharmaceuticals Incorporated Stock Price stock today
news today LGND – Ligand Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch LGND – Ligand Pharmaceuticals Incorporated yahoo finance google finance
stock history LGND – Ligand Pharmaceuticals Incorporated invest stock market
stock prices LGND premarket after hours
ticker LGND fair value insiders trading